Pulmatrix Inc. | Ownership
Companies that own Pulmatrix Inc.
Parallax Volatility Advisers LP
979,183
2.09%
79,183
0.01%
06/30/2018
The Vanguard Group, Inc.
652,473
1.39%
262,619
0%
06/30/2018
BlackRock Fund Advisors
291,604
0.62%
-28,654
0%
06/30/2018
Geode Capital Management LLC
190,220
0.41%
150,514
0%
06/30/2018
Virtu Financial BD LLC
42,259
0.09%
42,259
0%
06/30/2018
Northern Trust Investments, Inc.
39,434
0.08%
21,987
0%
06/30/2018
UBS Securities LLC
27,475
0.06%
22,527
0%
06/30/2018
Glenmede Investment Management LP
25,994
0.06%
0
0%
06/30/2018
The Bank of New York Mellon Corp. (Investment Management)
17,292
0.04%
0
0%
06/30/2018
SSgA Funds Management, Inc.
13,500
0.03%
0
0%
06/30/2018
| Address |
99 Hayden Avenue
Lexington Massachusetts 02421
United States
|
|
Employees
|
- |
| Website |
http://www.pulmatrix.com |
| Updated |
07/08/2019 |
| Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The company focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. |
